Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6519
    -0.0017 (-0.26%)
     
  • OIL

    83.11
    +1.76 (+2.16%)
     
  • GOLD

    2,254.80
    +42.10 (+1.90%)
     
  • Bitcoin AUD

    108,531.34
    +2,682.21 (+2.53%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6036
    +0.0006 (+0.09%)
     
  • AUD/NZD

    1.0902
    +0.0022 (+0.20%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Amgen Earnings, Revenue Beat in Q4

Amgen Earnings, Revenue Beat in Q4
Amgen Earnings, Revenue Beat in Q4

Investing.com - Amgen (NASDAQ:AMGN) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.

Amgen announced earnings per share of $3.64 on revenue of $6.20B. Analysts polled by Investing.com anticipated EPS of $3.4 on revenue of $6.02B. That with comparison to EPS of $3.42 on revenue of $6.23B in the same period a year before. Amgen had reported EPS of $3.66 on revenue of $5.74B in the previous quarter. Analysts are expecting EPS of $3.88 and revenue of $6.06B in the upcoming quarter.

Amgen shares are down 6.21% from the beginning of the year and are trading at $225.00 , still down 7.71% from its 52 week high of $244.99 set on December 17, 2019. They are under-performing the Nasdaq 100 which is up 3.79% year to date.

ADVERTISEMENT

Amgen shares lost 0.49% in after-hours trade after the report.

Amgen follows other major Healthcare sector earnings this month

Amgen's report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.

Novartis ADR had beat expectations on Wednesday with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Related Articles

Visa quarterly profit rises 10% on strong holiday season spending

U.S. securities regulator to monitor companies' coronavirus impact disclosures

Amazon.com Delivers Blowout Earnings in Q4 as Retail Growth Soars